
Thomas G Beach

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8758818/publications.pdf Version: 2024-02-01



THOMAS C. REACH

#	Article	IF	CITATIONS
1	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.1	2,805
2	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
3	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 2011, 43, 436-441.	21.4	1,676
4	Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. Journal of Neuropathology and Experimental Neurology, 2012, 71, 266-273.	1.7	797
5	Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathologica, 2010, 119, 689-702.	7.7	758
6	Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathologica, 2009, 117, 613-634.	7.7	553
7	A High-Density Whole-Genome Association Study Reveals That APOE Is the Major Susceptibility Gene for Sporadic Late-Onset Alzheimer's Disease. Journal of Clinical Psychiatry, 2007, 68, 613-618.	2.2	484
8	Low clinical diagnostic accuracy of early vs advanced Parkinson disease. Neurology, 2014, 83, 406-412.	1.1	395
9	<scp>A</scp> rizona <scp>S</scp> tudy of <scp>A</scp> ging and <scp>N</scp> eurodegenerative <scp>D</scp> isorders and <scp>B</scp> rain and <scp>B</scp> ody <scp>D</scp> onation <scp>P</scp> rogram. Neuropathology, 2015, 35, 354-389.	1.2	336
10	Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathologica, 2009, 117, 169-74.	7.7	193
11	Parkinson Disease With Dementia. Alzheimer Disease and Associated Disorders, 2009, 23, 295-297.	1.3	183
12	Postmortem interval effect on RNA and gene expression in human brain tissue. Cell and Tissue Banking, 2011, 12, 311-318.	1.1	127
13	Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology, 2014, 82, 858-864.	1.1	120
14	Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects. Neuroscience Letters, 2014, 571, 34-38.	2.1	115
15	Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2013, 72, 130-136.	1.7	106
16	Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease. BMC Medical Genomics, 2015, 9, 5.	1.5	103
17	In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease. Neurology, 2020, 95, e1267-e1284.	1.1	91
18	Parkinson disease and incidental Lewy body disease. Neurology, 2015, 85, 1670-1679.	1.1	88

Тномаѕ С Веасн

#	Article	lF	CITATIONS
19	TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies. Acta Neuropathologica, 2013, 126, 51-57.	7.7	82
20	Gender Differences in Alzheimer Disease: Brain Atrophy, Histopathology Burden, and Cognition. Journal of Neuropathology and Experimental Neurology, 2016, 75, 748-754.	1.7	82
21	Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques. JAMA Neurology, 2015, 72, 1124.	9.0	78
22	Probable RBD is increased in Parkinson's disease but not in essential tremor or restless legs syndrome. Parkinsonism and Related Disorders, 2011, 17, 456-458.	2.2	73
23	The Search for a Peripheral Biopsy Indicator of α-Synuclein Pathology for Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2017, 76, nlw103.	1.7	73
24	Effect of ApoE isoforms on mitochondria in Alzheimer disease. Neurology, 2020, 94, e2404-e2411.	1.1	71
25	Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 1260-1262.	2.2	68
26	Peripheral <scp>S</scp> ynucleinopathy in <scp>E</scp> arly <scp>P</scp> arkinson's <scp>D</scp> isease: <scp>S</scp> ubmandibular <scp>G</scp> land <scp>N</scp> eedle <scp>B</scp> iopsy <scp>F</scp> indings. Movement Disorders, 2016, 31, 250-256.	3.9	66
27	Striatal Amyloid Plaque Density Predicts Braak Neurofibrillary Stage and Clinicopathological Alzheimer's Disease: Implications for Amyloid Imaging. Journal of Alzheimer's Disease, 2012, 28, 869-876.	2.6	65
28	Clinicopathological Outcomes of Prospectively Followed Normal Elderly Brain Bank Volunteers. Journal of Neuropathology and Experimental Neurology, 2014, 73, 244-252.	1.7	65
29	Substantia Nigra Marinesco Bodies Are Associated with Decreased Striatal Expression of Dopaminergic Markers. Journal of Neuropathology and Experimental Neurology, 2004, 63, 329-337.	1.7	58
30	Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders. Journal of Parkinson's Disease, 2016, 6, 153-163.	2.8	58
31	Alzheimer Disease. Mayo Clinic Proceedings, 2017, 92, 978-994.	3.0	57
32	Alzheimer's Disease Neuropathological Comorbidities are Common in the Younger-Old. Journal of Alzheimer's Disease, 2021, 79, 389-400.	2.6	44
33	Neuropathologic Heterogeneity Does Not Impair Florbetapir-Positron Emission Tomography Postmortem Correlates. Journal of Neuropathology and Experimental Neurology, 2014, 73, 72-80.	1.7	36
34	Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment. BMC Neurology, 2015, 15, 146.	1.8	36
35	A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley?. Neurology and Therapy, 2017, 6, 5-13.	3.2	34
36	Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease. PLoS ONE, 2019, 14, e0217566.	2.5	31

Тномаѕ С Веасн

#	Article	IF	CITATIONS
37	Theoretical Impact of Florbetapir (¹⁸ F) Amyloid Imaging on Diagnosis of Alzheimer Dementia and Detection of Preclinical Cortical Amyloid. Journal of Neuropathology and Experimental Neurology, 2014, 73, 948-953.	1.7	29
38	Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer's disease dementia. PLoS ONE, 2020, 15, e0231720.	2.5	27
39	Next-generation profiling to identify the molecular etiology of Parkinson dementia. Neurology: Genetics, 2016, 2, e75.	1.9	25
40	Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions. Journal of Alzheimer's Disease, 2014, 42, 813-821.	2.6	22
41	Alzheimer's Disease and the "Valley of Death― Not Enough Guidance from Human Brain Tissue?. Journal of Alzheimer's Disease, 2012, 33, S219-S233.	2.6	20
42	Predicting alpha-synuclein pathology by REM sleep behavior disorder diagnosis. Parkinsonism and Related Disorders, 2018, 55, 92-96.	2.2	19
43	Reduced clinical and postmortem measures of cardiac pathology in subjects with advanced Alzheimer's Disease. BMC Geriatrics, 2011, 11, 3.	2.7	18
44	Association of AEBP1 and NRN1 RNA expression with Alzheimer's disease and neurofibrillary tangle density in middle temporal gyrus. Brain Research, 2019, 1719, 217-224.	2.2	15
45	Effect of olfactory bulb pathology on olfactory function in normal aging. Brain Pathology, 2022, 32, e13075.	4.1	13
46	Improved diagnosis of Parkinson's disease from a detailed olfactory phenotype. Annals of Clinical and Translational Neurology, 2017, 4, 714-721.	3.7	12
47	Co-Existence of tau and α-synuclein pathology in fetal graft tissue at autopsy: A case report. Parkinsonism and Related Disorders, 2020, 71, 36-39.	2.2	11
48	Feasibility Study: Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2015, 74, 934-942.	1.7	10
49	Hypermethylation of Synphilin-1, Alpha-Synuclein-Interacting Protein (SNCAIP) Gene in the Cerebral Cortex of Patients with Sporadic Parkinson's Disease. Brain Sciences, 2017, 7, 74.	2.3	9
50	Olfaction in Neuropathologically Defined Progressive Supranuclear Palsy. Movement Disorders, 2021, 36, 1700-1704.	3.9	7
51	Olfactory Bulb Amyloid- \hat{I}^2 Correlates With Brain Thal Amyloid Phase and Severity of Cognitive Impairment. Journal of Neuropathology and Experimental Neurology, 2022, 81, 643-649.	1.7	4
52	Clinical Diagnostic Accuracy of Early/Advanced Parkinson Disease: An Updated Clinicopathologic Study. Neurology: Clinical Practice, 2021, 11, e414-e421.	1.6	1
53	Neuropathological diagnoses of subjects autopsied in the phaseÂ3 clinicopathological study of flortaucipir F18 PET imaging. Alzheimer's and Dementia, 2020, 16, e040458.	0.8	0